X4 Pharmaceuticals, Inc. (XFOR) Revenue History
Annual and quarterly revenue from 2015 to present
XFOR Revenue Over Time (2015–2025)
XFOR Revenue Growth History
1 of 2 years with positive growth- FY2015 revenue growth
- N/A
- FY2016 revenue growth
- N/A
- FY2017 revenue growth
- N/A
- FY2018 revenue growth
- N/A
- FY2019 revenue growth
- N/A
- FY2020 revenue growth
- N/A
- FY2021 revenue growth
- -100.0%
- FY2022 revenue growth
- N/A
- FY2023 revenue growth
- N/A
- FY2024 revenue growth
- N/A
- FY2025 revenue growth
- +1273.2%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $2.7M | -90.6% |
| Q4 2025 | $2.6M | +79.1% |
| Q3 2025 | $1.8M | +215.2% |
| Q2 2025 | $2.0M | +250.4% |
| Q1 2025 | $28.8M | — |
| Q4 2024 | $1.4M | — |
| Q3 2024 | $560K | — |
| Q2 2024 | $563K | — |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2025)
XFOR's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
XFOR Revenue Analysis (2015–2025)
Current Revenue & Growth
As of June 12, 2026, X4 Pharmaceuticals, Inc. (XFOR) generated trailing twelve-month (TTM) revenue of $9.0 million, reflecting significant decline in growth of -90.6% year-over-year. The most recent quarter (Q1 2026) recorded $2.7 million in revenue, up 5.5% sequentially.
Historical Growth Trajectory
XFOR's 5-year compound annual growth rate (CAGR) stands at +63.6%, indicating outstanding long-term growth trajectory. X4 Pharmaceuticals, Inc.'s highest annual revenue of $35.1 million was recorded in 2025, an all-time high.
Revenue by Segment
XFOR's revenue is primarily driven by License and Other Revenue (81%), and Product (19%). With over half of revenue concentrated in License and Other Revenue, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Healthcare sector peers — including CYCN (-4.2% YoY), KYMR (-12.6% YoY), and ARDX (+18.2% YoY) — XFOR has underperformed the peer group in revenue growth. Compare XFOR vs CYCN →
XFOR Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
 XFORCurrent | $9M | -90.6% | +63.6% | -247.4% | |
 CYCN | $2M | -4.2% | -2.0% | -239.8% | |
 KYMR | $39M | -12.6% | +2.9% | -891.3% | |
 ARDX | $407M | +18.2% | +121.9% | -10.1% |
XFOR Historical Revenue Data (2015–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $35.1M | +1273.2% | $28.9M | 82.2% | $-86,883,000 | -247.4% |
| 2024 | $2.6M | - | $1.8M | 68.8% | $-36,401,000 | -1423.6% |
| 2023 | $0 | - | $0 | - | $-107,522,000 | - |
| 2022 | $0 | - | $0 | - | $-87,569,000 | - |
| 2021 | $0 | -100.0% | $-1,892,000 | - | $-75,349,000 | - |
| 2020 | $3.0M | - | $1.8M | 59.0% | $-59,874,000 | -1995.8% |
| 2019 | $0 | - | $-672,000 | - | $-46,803,000 | - |
| 2018 | $0 | - | $-103,000 | - | $-29,085,000 | - |
| 2017 | $0 | - | $-195,000 | - | $-36,133,000 | - |
| 2016 | $0 | - | $-300,000 | - | $-24,346,000 | - |
| 2015 | $0 | - | $-400,000 | - | $-14,825,000 | - |
What if you invested $1,000 in XFOR back in 2015?
Total return with dividends reinvested · 11+ years of data
Calculate ReturnsHow much would $100/month in XFOR be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs XFOR Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationXFOR vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowXFOR — Frequently Asked Questions
Quick answers to the most common questions about buying XFOR stock.
Is XFOR's revenue growth accelerating or slowing?
XFOR revenue is declining -90.6% year-over-year. TTM revenue fell to $9M, contrasting with the 5-year CAGR of +63.6%. The reversal reflects either macro headwinds or company-specific challenges.
What is XFOR's revenue history from 2015 to 2026?
X4 Pharmaceuticals, Inc. (XFOR) revenue history spans 2015 to 2026. TTM revenue as of 2026 is $9M, growing at -90.6% YoY. The 5-year CAGR is +63.6%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is XFOR's long-term revenue growth rate (CAGR)?
X4 Pharmaceuticals, Inc.'s 5-year revenue CAGR of +63.6% reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of -90.6% is below this long-term average. CAGR is the most reliable measure of sustained revenue momentum for XFOR.
Why does XFOR's quarterly revenue fluctuate?
XFOR quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. X4 Pharmaceuticals, Inc.'s revenue data from 2015 to 2026 shows full historical quarterly detail on this page.
How is XFOR's revenue distributed by segment?
XFOR reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does XFOR's revenue compare to industry peers?
X4 Pharmaceuticals, Inc. (XFOR) with TTM revenue of $9M and -90.6% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.